ÂÜÀòÂÒÂ×

Christina Trojel-Hansen PhD has a diverse work experience with various roles and responsibilities. Christina started their career as an Adjunct Assistant Professor at the University of Rochester Medical Center in June 2018. In January 2020, they co-founded Tune Therapeutics and served as the founding CEO, focusing on utilizing the epigenome to treat complex diseases and unlock the potential of regenerative medicine. Christina also co-founded Pretzel Therapeutics in February 2019, which aimed to modulate mitochondrial function for therapeutic purposes. Additionally, Christina Trojel-Hansen has experience as a Co-Founder and CEO at CNS2 (stealth), a Co-Founder at Comorin (stealth), and a consultant at Trojel Inc. In their role as an Entrepreneur In Residence at BioInnovation Institute from October 2019 to September 2020, they provided valuable insights and guidance. Prior to these roles, they co-founded Oscine Therapeutics in September 2017, where they served as the CEO until September 2020. Oscine Therapeutics focused on cell therapy for CNS and myelin diseases. Christina also served as a member of the Therapeutics Advisory Group at BioInnovation Institute. In 2018, they became an Entrepreneur in Residence at the institute. Currently, they are an Entrepreneur in Residence at ARCH Venture Partners and Saisei Ventures.

Christina Trojel-Hansen PhD obtained their MSc degree in Nanotechnology/Nanobiotechnology/Advanced Materials from the Interdisciplinary Nanoscience Center (iNANO) in Aarhus, Denmark, where they studied from 2003 to 2008. Christina pursued further education and completed an Industrial PhD program at the University of Copenhagen and the University of California Berkeley from 2008 to 2011, specializing in Drug Discovery. In 2015 and 2016, they attended the Denmark Technical University Executive School of Business and earned a Certificate in Entrepreneurial Leadership - CELâ„¢ (MBA).